Lurbinectedin

For research use only. Not for therapeutic Use.

  • CAT Number: I013699
  • CAS Number: 497871-47-3
  • Molecular Formula: C₄₁H₄₄N₄O₁₀S
  • Molecular Weight: 784.87
  • Purity: 98%
Inquiry Now

Lurbinectedin (Cat No.:I013699) is a novel anticancer agent that functions as a DNA minor groove binder. It exhibits potent anti-tumor activity by forming covalent adducts with DNA, resulting in DNA damage and inhibition of DNA transcription and replication. Lurbinectedin has shown efficacy against a variety of cancer types, including ovarian cancer, small-cell lung cancer, and soft-tissue sarcomas. It specifically targets cancer cells and has demonstrated selective cytotoxicity towards tumor cells while sparing normal cells. The compound’s ability to inhibit the growth of RMG1 and RMG2 cells with high potency highlights its potential as an effective anticancer therapy.


Catalog Number I013699
CAS Number 497871-47-3
Molecular Formula C₄₁H₄₄N₄O₁₀S
Purity 98%
Target CYP3A4
Target Protein

P08684

Solubility DMSO: 10 mM
Appearance Solid
Storage Dry, dark and at 2 - 8 °C for six months or -20°C for two years.
IC50 IC50: 1.25 nM (RMG1), 1.16 nM (RMG2)
IUPAC Name [(1R,2R,3R,11S,12S,14R,26R)-5,12-dihydroxy-6,6'-dimethoxy-7,21,30-trimethyl-27-oxospiro[17,19,28-trioxa-24-thia-13,30-diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]triaconta-4(9),5,7,15,20,22-hexaene-26,1'-2,3,4,9-tetrahydropyrido[3,4-b]indole]-22-yl] acetate
InChI InChI=1S/C41H44N4O10S/c1-17-11-20-12-25-39(48)45-26-14-52-40(49)41(38-22(9-10-42-41)23-13-21(50-5)7-8-24(23)43-38)15-56-37(31(45)30(44(25)4)27(20)32(47)33(17)51-6)29-28(26)36-35(53-16-54-36)18(2)34(29)55-19(3)46/h7-8,11,13,25-26,30-31,37,39,42-43,47-48H,9-10,12,14-16H2,1-6H3/t25-,26-,30+,31+,37+,39-,41+/m0/s1
InChIKey YDDMIZRDDREKEP-HWTBNCOESA-N
SMILES CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=C(CCN8)C2=C(N9)C=CC(=C2)OC)OCO7)C)OC(=O)C)C(=C1OC)O
Reference

1. Takahashi R, et al. Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary. PLoS One. 2016 Mar 17;11(3):e0151050.<br />
2. Leal JF, et al. PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity. Br J Pharmacol. 2010 Nov;161(5):1099-110.<br />
3. Vidal A, et al. Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer. Clin Cancer Res. 2012 Oct 1;18(19):5399-411.

Request a Quote